Samuel L. Aitken

Samuel L. Aitken

Auto-generated profile, based on publicly available information

Samuel L. Aitken

Department of Pharmacy Michigan Medicine Ann Arbor Michigan USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2017 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
JMJose Munita
Jose Munita
SASamuel L Aitken
Samuel L Aitken
WMWilliam R Miller
William R Miller
FPFederico Perez
Federico Perez
RRRossana Rosa
Rossana Rosa
CACesar A Arias
Cesar A Arias
A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication and treatment was successful in 26 (74%). Treatment failure was observed in all cases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations ≥8 μg/mL.

8 April 2021 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
JSJoseph Sassine
Joseph Sassine
FKFareed Khawaja
Fareed Khawaja
TSTerri Lynn Shigle
Terri Lynn Shigle
VHVictoria Handy
Victoria Handy
FFFarnaz Foolad
Farnaz Foolad
RCRoy F. Chemaly
Roy F. Chemaly
Background: Cytomegalovirus (CMV) reactivation is one of the most common infectious complications after allogeneic hematopoietic cell transplant (HCT) and may result in significant morbidity and mortality. Primary prophylaxis with letermovir demonstrated a reduction in clinically significant CMV infections (CS-CMVi) in clinical trials of CMV-seropositive HCT recipients. This study aims at exploring the effect of primary letermovir prophylaxis in this population on the incidence and outcomes of refractory or resistant CMV infections. Methods: This is a single-center, retrospective cohort study of 537 consecutive CMV-seropositive allogeneic HCT recipients cared for between March 2016 and October 2018. Baseline demographics, HCT characteristics, CMV infections, treatment, and mortality data were collected from the electronic medical record. CMV outcomes were defined according to the recently standardized definitions for clinical trials. Characteristics and outcomes were assessed according to receipt of primary letermovir prophylaxis. Results: Of 537 patients identified, 123 received letermovir for primary prophylaxis during the first 100 days after HCT; 414 did not. In a multivariate analysis, primary prophylaxis with letermovir was associated with reductions in CS-CMVi (hazard ratio [HR] 0.26; 95% confidence interval [CI], 0.16–0.41), CMV end-organ disease (HR 0.23; 95% CI, 0.10–0.52), refractory or resistant CMV infection (HR 0.15; 95% CI, 0.04–0.52), and nonrelapse mortality at week 48 (HR 0.55; 95% CI, 0.32–0.93). There was neither resistant CMV nor CMV-related mortality in the primary letermovir prophylaxis group. Conclusions: Primary letermovir prophylaxis effectively prevents refractory or resistant CMV infections and decreases nonrelapse mortality at week 48, as well as CS-CMVi and CMV disease after allogeneic HCT.

1 August 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
FTFrank P. Tverdek
Frank P. Tverdek
SHSang Taek Heo
Sang Taek Heo
SASamuel L. Aitken
Samuel L. Aitken
BGBruno Granwehr
Bruno Granwehr
Dimitrios P. KontoyiannisDimitrios P. Kontoyiannis
Dimitrios P. Kontoyiannis
Posaconazole is the preferred mold-active azole for prophylaxis against invasive fungal infections (IFIs) in patients with hematological malignancy. Delayed-release tablet and intravenous formulations of posaconazole have recently become available, but clinical data are limited. We sought to examine the real-world pharmacokinetics and prophylactic effectiveness of the new formulations of posaconazole given as prophylaxis for patients with hematological malignancy. A retrospective cohort of all consecutive adult inpatients with hematological malignancy who received ≥3 days of tablet or intravenous posaconazole therapy for primary IFI prophylaxis at the M. D. Anderson Cancer Center between 1 December 2013 and 31 December 2015 was established. Clinical information was collected and correlated with low posaconazole serum levels (<700 ng/ml). Rates of IFIs and safety events were assessed. A total of 1,321 courses of posaconazole were administered at the M. D. Anderson Cancer Center during the study period, of which 343 courses were assessed for prophylactic safety and effectiveness. Seventy-nine patients (23%) had posaconazole serum level measurements available for interpretation. Acute myeloid leukemia was the primary malignancy (62%), with 20% of all patients having previously received a stem cell transplant. The median posaconazole level was 1,380 ng/ml (interquartile range, 864 to 1,860 ng/ml). Low posaconazole levels (1,830 ng/ml. Although hepatotoxicity in a small percentage of patients is of concern, posaconazole tablets appeared to be generally safe and effective. As all breakthrough IFIs for which TDM was performed occurred in patients with levels of >700 ng/ml, and a posaconazole level of >1,830 ng/ml was correlated with grade 3 or 4 liver toxicity, further studies are needed to assess the role of TDM.

6 May 2019 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
J Kevin HicksJ Kevin Hicks
J Kevin Hicks
CAChristina L. Aquilante
Christina L. Aquilante
HDHenry Dunnenberger
Henry Dunnenberger
RGRoseann S. Gammal
Roseann S. Gammal
RFRyan S. Funk
Ryan S. Funk
JLJames C. Lee
James C. Lee

3 May 2017 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
SSSamuel A. Shelburne
Samuel A. Shelburne
JKJiwoong Kim
Jiwoong Kim
JMJose M Munita
Jose M Munita
PSPranoti Sahasrabhojane
Pranoti Sahasrabhojane
RSRyan K Shields
Ryan K Shields
DGDavid E Greenberg
David E Greenberg
There is marked interest in using DNA-based methods to detect antimicrobial resistance (AMR), with targeted polymerase chain reaction (PCR) approaches increasingly being incorporated into clinical care. Whole-genome sequencing (WGS) could offer significant advantages over targeted PCR for AMR detection, particularly for species where mutations are major drivers of AMR. Illumina MiSeq WGS and broth microdilution (BMD) assays were performed on 90 bloodstream isolates of the 4 most common gram-negative bacteria causing bloodstream infections in neutropenic patients. The WGS data, including both gene presence/absence and detection of mutations in an array of AMR-relevant genes, were used to predict resistance to 4 β-lactams commonly used in the empiric treatment of neutropenic fever. The genotypic predictions were then compared to phenotypic resistance as determined by BMD and by commercial methods during routine patient care. Of 133 putative instances of resistance to the β-lactams of interest identified by WGS, only 87 (65%) would have been detected by a typical PCR-based approach. The sensitivity, specificity, and positive and negative predictive values for WGS in predicting AMR were 0.87, 0.98, 0.97, and 0.91, respectively. Using BMD as the gold standard, our genotypic resistance prediction approach had a significantly higher positive predictive value compared to minimum inhibitory concentrations generated by commercial methods (0.97 vs 0.92; P = .025). These data demonstrate the potential feasibility of using WGS to guide antibiotic treatment decisions for patients with life-threatening infections for an array of medically important pathogens.

1 September 2016 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
MMMaria Mojica
Maria Mojica
COChristopher P. Ouellette
Christopher P. Ouellette
ALAmy Leber
Amy Leber
MBM. Brian Becknell
M. Brian Becknell
MAMonica I. Ardura
Monica I. Ardura
SSSamuel A. Shelburne
Samuel A. Shelburne
Stenotrophomonas maltophilia is an emerging multidrug-resistant (MDR) opportunistic pathogen for which new antibiotic options are urgently needed. We report our clinical experience treating a 19-year-old renal transplant recipient who developed prolonged bacteremia due to metallo-β-lactamase-producing S. maltophilia refractory to conventional treatment. The infection recurred despite a prolonged course of colistimethate sodium (colistin) but resolved with the use of a novel drug combination with clinical efficacy against the patient's S. maltophilia isolate.